/ NKTR
/ Market Analysis
Why Is Nektar (NKTR) Stock Up 17% Premarket Today? Positive AD Trial Data
Nektar stock jumped more than 17% in premarket trading after the company reported positive 52-week data from its REZOLVE-AD atopic dermatitis trial.
February 10, 2026
Nektar Therapeutics (NKTR) Jumps 116% in Premarket After Positive Trial Results
Nektar Therapeutics stock surged 116% in premarket trading after announcing successful Phase 2b trial results for its atopic dermatitis treatment.
June 24, 2025
Back to 
